contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-collected-52-meur-in-gross-assets-from-the-directed-share-issue-as-expected

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Herantis Pharma plc **Espoo, Finland, March 16, 2026:**Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri Huttunen, will be delivering an oral presentation at the 20thInternational Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026), held in Denmark from 17-21 March, on data from Herantis’s Phase 1b trial of HER-096 in people living with Parkinson’s disease (PD). Henri will present previously disclosed safety, tolerability, pharmacokinetic and biomarker data from 24 people living with PD who received 200 mg or 300 mg of HER-096 or placebo, repeated twice a week for four weeks. The results met all primary and secondary endpoints, demonstrating that HER-096 was safe and well tolerated. The data also showed that both dose levels of HER-096 achieved sufficient maximum concentration and total exposure in cerebrospinal fluid (CSF) to reach the expected pharmacologically active levels, confirming the ability of HER-096 to cross the blood-brain barrier in individuals living with PD. Biomarker analyses from the Phase 1b trial showed clear clinical evidence of biological response to HER-096 exposure in people with Parkinson’s disease. Across 2.5 million datapoints, HER-096 was shown to modulate Parkinson’s disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, aligned with the expected mechanism of action. Henri Huttunen, CSO of Herantis Pharma, said: “I am looking forward to presenting these clinically meaningful Phase 1b results at AD/PD 2026, to highlight the significant potential of the HER-096 program as a disease-modifying therapy for the 10 million people living with PD globally. Having established safety, tolerability, pharmacokinetics and biological activity in-line with our expectations, we have a robust dataset forming the foundations of our preparations for a Phase 2 proof-of-concept study.” Presentation details:  Session: Modulating neuroinflammation, α-synuclein, LRRK2, and dopaminergic repair: early human data Title: A Phase 1b study to investigate safety, tolerability and biomarker responses of repeated subcutaneous doses of HER-096 in subjects with Parkinson’s disease Presenter: Henri J. Huttunen (Finland) Date/Time: Wednesday, 18 March 2026; 14:45 - 15:00 CET Room: Hall 180-181  For more information, please contact: Herantis Pharma:  Tone Kvåle, CFO  Tel: +47 915 19576  Email: ir@herantis.com ICR Healthcare: Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage  Tel: +44 20 3709 5700  Email: herantispharma@icrhealthcare.com Certified Advisor:  UB Corporate Finance Ltd  Tel.: +358 9 25 380 225  E-mail: ubcf@unitedbankers.fi

CFO added a small slice.                   Inderes              Herantis Pharma Oyj: Johdon liiketoimet – Tone Kvåle - Inderes    Herantis Pharma OyjYhtiötiedote 10.3.2026 kello 13:00Herantis Pharma Oyj: Johdon liiketoimet – Tone KvåleHerantis Pharma Oyj - Johdon liiketoimet____________________________________________Ilmoitusvel...

A clear answer regarding the outlook for the formation of Herantis Pharma’s partnership agreement. https://x.com/ristopar/status/2030476177870131641/video/1

Here is a fresh company report from Antti regarding Herantis’s H2  Herantis’s main theme for 2025 was the completion of the Phase I study. All objectives of the study were achieved, providing a solid scientific basis for the future. The company’s estimate of the remaining funding requirement for the Phase II study is 20–25 MEUR, which is in line with our forecast. The next critical step is securing funding for the study, which in our assessment involves significant binary risk depending on the solution reached. We are modeling our estimate for follow-on funding and adjusting our target price to EUR 2.4 (prev. EUR 2.5) following the changes. We upgrade our recommendation to Accumulate (prev. Reduce) as the share price decline has improved the risk-reward ratio.                   Inderes              Herantis H2'25: Rahoitus kuntoon ja uuden tutkimuksen alkuun - Inderes    Herantis valmistautuu rahoitusratkaisuihin ja seuraavan tutkimuksen aloittamiseen.

Good interview of Antti by Antti. Vuolanto’s demeanor is quite confident and calm. 2025 went successfully, results were good and the feedback from Big Pharma (BP) and experts was excellent. This year has started off brilliantly regarding Phase II funding, and his answers really exude positive confidence that the funding will be secured on schedule.                   Inderes              Herantis Pharma H2'25: Vahva pohja vaiheen II tutkimuksen aloittamiselle -...    Aika: 05.03.2026 klo 12.06 Herantis Pharma eteni vuonna 2025 suunnitelmien mukaisesti ja vaiheen 1b tutkimus saavutti tavoitteet.

In my opinion, Herantis Pharma’s communications have been of very high quality in all respects. Essential matters have been reported well in advance and according to the actual situation, to the extent permitted by the Companies Act.

I don’t know, but could a major problem for Finnish listed companies be equal disclosure and the treatment of owners? Nowadays, as information is exchanged on forums like this, the companies themselves end up as the ones suffering when all investors do not have the same information. As a result, the market values of companies move by incomprehensible amounts in short periods of time. Herantis’s €4.2 million directed issue just before the announcement of the €8 million from Horizon Europe. A perfectly legal thing that just happened to occur at the same time? Is it time to make changes to stock exchange regulations? Since technology would allow it today, why not make subscribing easier so that all owners could participate? I wonder when the laws were last updated? And thinking a bit more generally, when Finnish companies “muddle through” (while complying with the law), then when it’s time for a big leap, these companies are “taken.” Why? Perhaps because those who have had the opportunity to invest money in the company have already gotten their share or have been getting it along the way. And when it is time for big decisions (partnering/sales deals), these same people make the decisions or provide strong recommendations. Money tends to follow money more and more. The way we could get our country on the rise would be the spreading of wealth, not its narrowing. We have seen around the world where that eventually leads. Hopefully, in the case of Herantis, transparency will continue in communications, for example, regarding partnership discussions.

Herantis Pharma

The funds raised in the issue will strengthen the company's financial position until the topline data of the HER-096 phase 1b trial are released in Q3'25. The company commented that it will continue its partnership discussions and preparations for the phase 2 trial. 

Translation: Original published in Finnish on 02/07/2025 at 8:00 am EET
The funds raised <a href="https://www.inderes.se/releases/inside-information-herantis-pharma-plc-successfully-completes-a-directed-share-issue-raising-eur-52-million">in the issue</a> will strengthen the company&apos;s financial position until the topline data of the HER-096 phase 1b trial are released in Q3&apos;25. The company commented that it will continue its partnership discussions and preparations for the phase 2 trial. The share issue will be carried out at a price of EUR 1.32 per share, which represents a discount of -12% to yesterday&apos;s closing price of EUR 1.5 per share and raises the company&apos;s number of shares by some 20%. The funding is almost exactly in line with our expectations in size (Assumption: 5 MEUR), timing (Assumption: early 2025) and valuation (Assumption: EUR 1.36 per share) and therefore contains no surprises. Thus, the release only necessitates minor revisions to our forecasts. We will update our forecasts and views on the company in connection with the financial statements release to be published on March 6.

	2023	24e	25e
Revenue	0.0	0.0	0.0
growth-%		150.0 %
EBIT (adj.)	0.2	-5.3	-5.0
EBIT-% (adj.)	3,850.0 %	-52,560.0 %	-49,520.0 %
EPS (adj.)	0.01	-0.26	-0.21
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	114.2	neg.	neg.
EV/EBITDA	165.2	neg.	neg.

Herantis Pharma collected 5.2 MEUR in gross assets from the directed share issue as expected

Key Estimate Figures23.08.2024

Forum discussions